Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.

Journal of translational medicine - 9 Jul 2024

Lund-Andersen Christin, Torgunrud Annette, Kanduri Chakravarthi, Dagenborg Vegar J, Frøysnes Ida S, Larsen Mette M, Davidson Ben, Larsen Stein G, Flatmark Kjersti

Abstract excerpt

BACKGROUND: Patients with peritoneal metastasis from colorectal cancer (PM-CRC) have inferior prognosis and respond particularly poorly to chemotherapy. This study aims to identify the molecular explanation for the observed clinical behavior and suggest novel treatment strategies in PM-CRC. METHODS: Tumor samples (230) from a Norwegian national cohort undergoing surgery and hyperthermic intraperitoneal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Targeted Therapy

Share to Mutation

Share to Peritoneal Neoplasms

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 38982444
DOI: 10.1186/s12967-024-05467-2
PMCID: PMC11234641

Genes

BRAF
BTN1A1
BTNL9
CES1
CYP3A4
KRAS
RNF43
SLC7A6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.PMID 38982444Read ↗

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancerSemantic proximity Read ↗

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with a hypermutant, hypermethylated stateSemantic proximity Read ↗

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.Semantic proximity Read ↗

Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

BRAFV600E-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities.Semantic proximity Read ↗

Impact of RAS, BRAF mutations and microsatellite status in peritoneal metastases from colorectal cancer treated with cytoreduction + HIPEC: scoping reviewSemantic proximity Read ↗

Whole genome sequencing of metastatic colorectal cancer reveals prior treatment effects and specific metastasis features.Semantic proximity Read ↗

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitorsSemantic proximity Read ↗

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.Semantic proximity Read ↗

Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.